This inventor holds 2 USPTO granted patents. Top assignee: Olix Pharmaceuticals, Inc.. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2020
Title: Young-Dong Kim: Innovator in RNA Therapeutics
Introduction
Young-Dong Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of RNA therapeutics, particularly in the treatment of idiopathic pulmonary fibrosis. With a total of two patents to his name, Kim is recognized for his innovative approaches to medical challenges.
Latest Patents
Young-Dong Kim's latest patents focus on the treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (CTGF). These RNA complexes, including asymmetric RNA complexes such as asiRNAs or cell-penetrating asiRNAs, are designed to inhibit CTGF expression. This innovative approach holds promise for effectively treating this challenging condition.
Career Highlights
Kim is currently associated with Olix Pharmaceuticals, Inc., where he continues to advance his research in RNA therapeutics. His work has garnered attention for its potential to transform treatment options for patients suffering from idiopathic pulmonary fibrosis.
Collaborations
Some of Young-Dong Kim's notable coworkers include Dong Ki Lee and Sun Woo Hong. Their collaborative efforts contribute to the innovative research environment at Olix Pharmaceuticals.
Conclusion
Young-Dong Kim's contributions to RNA therapeutics exemplify the impact of innovation in medicine. His work not only addresses critical health issues but also paves the way for future advancements in treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile